Quarry LP Trims Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Quarry LP lowered its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 62.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,285 shares of the company’s stock after selling 3,828 shares during the quarter. Quarry LP’s holdings in Hims & Hers Health were worth $55,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. raised its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $38,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 10.0 %

NYSE HIMS opened at $36.39 on Friday. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a fifty day moving average of $32.19 and a two-hundred day moving average of $31.30. The firm has a market capitalization of $8.09 billion, a price-to-earnings ratio of 82.72 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on HIMS. Leerink Partners boosted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. TD Cowen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating and reduced their price target for the company from $44.00 to $30.00 in a report on Tuesday. Piper Sandler boosted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Finally, Needham & Company LLC raised their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.92.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 33,333 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. This represents a 3.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $36.39, for a total transaction of $1,819,500.00. Following the completion of the sale, the chief executive officer now owns 92,103 shares of the company’s stock, valued at approximately $3,351,628.17. This represents a 35.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 666,234 shares of company stock valued at $26,387,645. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.